We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$249M
1-Year Est. Return
80.12%
This Fund
S&P 500
This Quarter
Est. Return
+40.59%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$480M
Cap. Flow
% of AUM
395.45%
Top 10 Holdings %
Top 10 Hldgs %
61.9%
Holding
30
New
30
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$6.84M |
| 2 |
Xeris Biopharma Holdings
XERS
|
+$6.54M |
| 3 |
ATXS
Astria Therapeutics
ATXS
|
+$6.24M |
| 4 |
OPTN
OptiNose
OPTN
|
+$5.94M |
| 5 |
Viridian Therapeutics
VRDN
|
+$5.69M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LYRA
1
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $9.9M | 8.15% |
+37,774
| New | +$6.84M |
|
2
Myomo
MYO
$38.6M
| $9.62M | 7.92% |
+1,919,910
| New | +$5.11M |
|
|
ATXS
3
DELISTED
Astria Therapeutics
ATXS
| $8.67M | 7.14% |
+1,128,708
| New | +$6.24M |
|
|
4
Xeris Biopharma Holdings
XERS
$1.45B
| $8.33M | 6.86% |
+3,543,685
| New | +$6.54M |
|
|
5
Viridian Therapeutics
VRDN
$2.2B
| $7.85M | 6.46% |
+360,332
| New | +$5.69M |
|
|
CMPS
6
Compass Pathways
CMPS
$1.56B
| $6.99M | 5.75% |
+798,500
| New | +$5.17M |
|
|
OPTN
7
DELISTED
OptiNose
OPTN
| $6.3M | 5.19% |
+325,705
| New | +$5.94M |
|
8
MediWound
MDWD
$181M
| $6.17M | 5.08% |
+606,751
| New | +$5.45M |
|
9
Madrigal Pharmaceuticals
MDGL
$11.4B
| $5.78M | 4.76% |
+25,000
| New | +$4.37M |
|
10
Cellectar Biosciences
CLRB
$20.2M
| $5.56M | 4.58% |
+66,855
| New | +$4.98M |
|
11
Sarepta Therapeutics
SRPT
$1.64B
| $5.54M | 4.56% |
+57,400
| New | +$5.51M |
|
|
VRNA
12
DELISTED
Verona Pharma
VRNA
| $4.97M | 4.09% |
+250,000
| New | +$3.69M |
|
|
SPRB
13
Spruce Biosciences
SPRB
$119M
| $4.65M | 3.83% |
+21,152
| New | +$2.44M |
|
|
PROF
14
Profound Medical
PROF
$263M
| $4.53M | 3.73% |
+533,333
| New | +$5.07M |
|
15
Delcath Systems
DCTH
$416M
| $4.32M | 3.56% |
+1,038,828
| New | +$3.4M |
|
|
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
| $3.67M | 3.03% |
+300,000
| New | +$2.73M |
|
17
Veru
VERU
$35.6M
| $2.88M | 2.37% |
+400,000
| New | +$3.55M |
|
18
InspireMD
NSPR
$31.5M
| $2.6M | 2.14% |
+925,194
| New | +$2.66M |
|
19
Trevi Therapeutics
TRVI
$2.61B
| $2.5M | 2.06% |
+1,862,425
| New | +$2.82M |
|
20
Ascendis Pharma A/S
ASND
$16.5B
| $2.12M | 1.74% |
+16,800
| New | +$1.67M |
|
21
Fortress Biotech
FBIO
$109M
| $1.83M | 1.51% |
+607,797
| New | +$1.61M |
|
|
NVNO
22
enVVeno Medical
NVNO
$7.1M
| $1.6M | 1.32% |
+8,917
| New | +$1.42M |
|
|
RVPH
23
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $1.01M | 0.83% |
+9,815
| New | +$881K |
|
|
24
PUT
Sarepta Therapeutics
SRPT
$1.64B
| $832K | 0.69% |
+57,400
| New | +$5.51M |
|
|
MACK
25
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $805K | 0.66% |
+60,000
| New | +$758K |
|
Similar funds
TAM
SCM
FDDB
MC
SCM
GWS
SCM
ER
Rosalind Advisors's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Rosalind Advisors, which disclosed 30 positions worth $121M. Its ten largest holdings account for 62% of the portfolio.
Its largest position is LYRA THERAPEUTICS INC: 37,774 shares worth $9.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets.
- Rosalind Advisors's largest Q4 2023 buy was LYRA THERAPEUTICS INC: 37,774 shares worth $9.9M.
- Rosalind Advisors's ten largest holdings make up 62% of its $121M portfolio in Q4 2023.
- Rosalind Advisors disclosed 30 positions in Q4 2023, its first 13F filing on record.
Based on Rosalind Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.